safety of compounded semaglutide Patient Updates Risks of compounded semaglutide products

High blood ammonia levels

The groundbreaking 2021 clinical trial of semaglutide still found that almost 14% of participants failed to even lose 5% of their body weight, even after taking the drug for more than one year

"The majority of people taking these medications do not experience any significant eye issues," says optometrist Meenal Agarwal, MD

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial conducted in the USA

Our article on GLP-1 vs Natural Weight Loss explores this in depth

Hydration matters more than most people realize during fat loss protocols